Vlasic Labs CBD Products Qualify for CMS CBD Pilot Program, Marking Historic Step for Cannabinoid Therapies

By PRNewswire ·

Burn After Reading
The 30-second intel for operators and investors

Vlasic Labs says its CBD line meets the qualifications of a CMS pilot that lets participating healthcare organizations provide eligible hemp-derived products to Medicare beneficiaries, with patient offerings beginning in April 2026.

  • Operators: Eligible products must meet strict federal standards for safety, dosing and THC content. Quality and compliance become the entry ticket for hemp brands that want to reach Medicare patients through healthcare providers.
  • Investors: The program is framed as a step toward mainstream legitimacy for non-intoxicating cannabinoids. The release gives no volumes, pricing or revenue figures, and the qualification claim comes from the company itself.
  • Do now: Compare your products' safety, dosing and THC specifications with the CMS program's published standards to see whether they would qualify, and flag any gaps in testing or documentation.
Short on time? You’re done. Want the numbers?Keep reading ↓

BLOOMFIELD HILLS, Mich. , March 31, 2026 /PRNewswire/ — Vlasic Labs today announced that its CBD product line meets the current qualifications outlined in the Centers for Medicare & Medicaid Services (CMS) pilot program, a first-of-its-kind initiative allowing participating healthcare organizations to provide eligible hemp-derived products to Medicare beneficiaries.

This milestone represents a significant step forward in legitimizing CBD as part of mainstream medical care, reinforcing the role of non-intoxicating cannabinoids in patient-centered treatment models. Under the CMS program, eligible hemp products must meet strict federal standards for safety, dosing, and THC content, further elevating the importance of quality and compliance across the category.

“For years, Vlasic Labs has been committed to producing high-quality, non-intoxicating CBD products formulated with consistency, rigorous testing, and transparency,” said Willy Vlasic, CEO of Vlasic Labs. “As the hemp industry has evolved, we’ve remained focused on building a brand that prioritizes long-term trust over short-term trends. Meeting CMS’s recently released standards reinforces that commitment, and we look forward to partnering with participants to help expand access to reliable cannabinoid products for Medicare patients.”

The hemp market has expanded rapidly in recent years, moving beyond CBD into a wide range of categories. Amid that growth, Vlasic Labs has maintained a clear and disciplined strategy, focusing on non-intoxicating formulations that align with medical use cases, regulatory stability, and trusted distribution channels.

As healthcare providers participating in CMS models begin offering these products to patients starting April 2026, Vlasic Labs will work alongside participating organizations to support program implementation and deliver high-quality products that continue to meet all regulatory requirements as the program evolves.

Related coverage

Image
PRNewswire
April 3, 2026
Share: